ABSTRACT
OBJECTIVE:
To investigate the
clinical efficacy and
safety of
cilostazol combined with
alprostadil in the
treatment of
peripheral arterial disease(PAD).
METHODS:
A total of 68 PAD
patients in our
hospital from Jan. 2015 to Jan. 2016 were di-vided into
observation group(34 cases)and
control group(34 cases)according to random number table.
Control group was given basical
treatment,and
Alprostadil injection 2 mL+0.9%
Sodium chloride injection 100 mL,ivgtt,qd.
Observation group was addi-tionally given
Cilostazol tablets 100 mg,po,bid,on the basis of
control group. Both groups were treated for 30 days. Clinical effi-cacies of 2 groups were observed. The
hemorheology indexes(
hematocrit,whole
blood high-shearing
viscosity,
erythrocyte aggre-gation index,
erythrocyte deformation index,
plasma viscosity),inflammatory factor indexes(TNF-α,
IL-6,
IL-8,
hs-CRP),oxida-tion stress indexes(GSH-Px,SOD,T-Aoc,MDA),
arteriosclerosis indexes(ABI,TBI,dorsalis pedis
artery blood flow)were de-termined before and
after treatment. The occurrence of ADR was recorded.
RESULTS:
Total response rate of
observation group (91.18%)was significantly higher than that of
control group(79.41%),with statistical significance(P0.05).
After treatment,
hematocrit,whole
blood high-shearing
viscosity,
erythrocyte aggregation index,
erythrocyte deformation index,
plasma viscosity,the levels of TNF-α,
IL-6,
IL-8,
hs-CRP and MDA in 2 groups were de-creased significantly;while the levels of GSH-Px,SOD,T-Aoc,ABI,TBI and dorsalis pedis
artery blood flow were increased sig-nificantly;the improvement of above indexes in
observation group was significantly better than
control group,with statistical signif-icance(P0.05).
CONCLUSIONS:
For PAD,
cilostazol combined with
alprostadil can effectively improve hemorheolo-gy indexes,inflammatory factor indexes,
oxidation stress indexes and
arteriosclerosis indexes with good
safety.